Do you want to read an article? Please log in or register.
The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study
Multiple Sclerosis
Related content
Multiple Sclerosis
Real Life Long-Term Effectiveness of Fingolimod in Swiss Patients with Relapsing-Remitting Multiple Sclerosis (REALITE)
doi: 10.1111/ene.13594.
SPECIAL REPORT
Multiple Sclerosis
Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis
RECOMMENDED
Multiple Sclerosis
Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study
Ther Adv Neurol Disord.
Kallmann BA, Tiel-Wilck K, Kullmann JS, Engelmann U, Chan A
doi: 10.1177/
Multiple Sclerosis
Multiple sclerosis in the real world: A systematic review of fingolimod as a case study
Autoimmun Rev.
Ziemssen T, Medin J, Anne-Marie Couto C, Mitchell CR
doi: 10.1016/j.autrev.2017.02.007.
RECOMMENDED
Multiple Sclerosis
Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
Mult Scler.
Naismith RT, Wolinsky JS, Wundes A, LaGanke C, Arnold DL, Obradovic D, Freedman MS, Gudesblatt M, Ziemssen T, Kandinov B, Bidollari I, Lopez-Bresnahan M, Nangia N, Rezendes D, Yang L, Chen H, Liu S, Hanna J, Miller C, Leigh-Pemberton R
doi: 10.1177/1352458519881761.
Aging and Cognitive FunctionsMultiple Sclerosis
Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)
J Neurol.
Comi G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P, Centonze D, Pozzilli C, Saccà F, Bergh FT, Bartezaghi M, Turrini R, Filippi M; Golden Study Group
doi: 10.1007/s00415-017-8642-5.
Multiple Sclerosis
Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program
Mult Scler.
Wiendl H, Spelman T, Butzkueven H, Kappos L, Trojano M, Su R, Campbell N, Ho PR, Licata S
doi: 10.1177/1352458520926869.
Multiple Sclerosis
Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study
Neurology.
Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, Buttari F, Centonze D, Cortese A, De Giglio L, Fantozzi R, Ferraro E, Fornasiero A, Francia A, Galgani S, Gasperini C, Marfia GA, Millefiorini E, Nociti V, Pontecorvo S, Pozzilli C, Ruggieri S, Salvetti M, Sgarlata E, Mirabella M
doi: 10.1212/WNL.
SPECIAL REPORT
Multiple Sclerosis